News
Four operating theatres delivered by MTX at Royal Bolton Hospital
MTX has completed a project to deliver four state- of-the-art operating theatres at the Royal Bolton Hospital using Modern Methods of Construction principles and modular offsite techniques to ensure rapid delivery. The company was initially awarded the contract
to deliver two new theatres at the hospital but the ambition of the Bolton NHS Foundation Trust was always to create four new theatres to enhance patient care and help minimise the backlog of surgeries resulting from the COVID-19 pandemic. In December 2022, the Trust announced success in its bid for £19.6 million funding to significantly increase its theatre capacity by creating all four new theatres and refurbishing existing day-case theatres to create a bespoke day case paediatrics theatre hub. Making optimum use of Modern Methods of Construction (MMC) principles enables MTX to minimise build times by up to 50% while creating high quality fully compliant facilities, and reduce waste by up to 60%. For the Royal Bolton Hospital project, MTX used off-site manufactured structural steel units and mechanical and electrical modules assembled on site to streamline delivery of the new facilities. The new theatres will provide enhanced capacity
for both Bolton and Greater Manchester and help to drive down waiting lists in the city-region. They have been built on the former staff car park near the Princess Anne maternity unit.
Sponsored by
Karl Storz acquires British AI specialist
MedTech company Karl Storz has announced the acquisition of the innovative software manufacturer Innersight Labs, (ISL) headquartered in London. Karl Storz is continuing to expand its
Annette Walker, Director of Finance at Bolton
NHS Foundation Trust, said: “Being able to increase the capacity of our theatres will enable us to provide even better patient experience and help us to tackle the backlog of elective waiting lists throughout Bolton and Greater Manchester.” The four ultra-modern theatres have been designed to work flexibly and adapt for inpatient and day case adult patients, including ear nose and throat, oral, urology and general specialties. Annette added: “Creating brand new and modern spaces at our hospital will be crucial as we continue to provide the highest levels of care for patients in Bolton both now and well into the future.”
software solutions, and the know-how gained with the acquisition in the field of AI will greatly enhance the company’s portfolio. ISL developed Innersight3D, a software-only product that allows surgeons to create a patient-specific 3D model from a medical CT or MRI scan. ISL labels received scans according to the different tissue types and creates an interactive 3D model. This can then be accessed and interacted with via a web link sent to the physician. Because of the more accurate preoperative assessment, benefits include reducing operation time and the risk of surgical complications. “We want to continue pioneering MedTech, particularly in the areas of software and robotics. The research background that ISL brings to the table fits ideally with our vision, mission, and strategic goals,” said Thorsten Molitor, Executive Vice President at Karl Storz. ISL also has in-depth knowledge of
soft tissue deformation and mechanics, computational physics, image processing and machine learning, as well as experience in cloud software development.
Landmark national study supports use of whole genome sequencing in standard cancer care
In the largest study of its kind, scientists have reported how combining health data with whole genome sequence (WGS) data in patients with cancer can help doctors provide more tailored care for their patients. The research, published in Nature Medicine,
shows that linking WGS data to real-world clinical data can identify changes in cancer DNA that may be relevant for an individual patient’s care, for example by helping identify what treatment might work best for them based on their cancer. The study, led by Genomics England, NHS
England, Queen Mary University of London, Guy’s and St Thomas’ NHS Foundation Trust and the University of Westminster, analysed data covering over 30 types of solid tumours collected from more than 13,000 participants with cancer in the 100,000 Genomes Project. By looking at the genomic data alongside routine clinical data,
12
www.clinicalservicesjournal.com I February 2024
better or worse survival rates and improved patient outcomes. The study showed that WGS could provide a more comprehensive view of a tumour’s genetic landscape by detecting various genetic changes using a single test. This research uncovered significant findings across different cancer types, such as: l Over 90% of brain tumours and over 50% of colon and lung cancers showed genetic changes that could affect how patients are treated, guiding decisions about surgery or specific treatments they might need.
collected from participants over a five-year period, such as hospital visits and the type of treatment they received, scientists were able to find specific genetic changes in the cancer associated with
l In more than 10% of sarcomas, larger DNA changes, known as structural variants, were identified that can impact clinical care and treatment.
l In over 10% of ovarian cancers, the study pinpointed inherited risks offering crucial insights for clinical care.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
